Skip to main content
. 2023 Feb 2;141(17):2114–2126. doi: 10.1182/blood.2022017333

Figure 4.

Figure 4.

Disease response over time in eftoza plus venetoclax combination cohorts. Response per the International Working Group. Disease progression is assessed per European LeukemiaNet. Samples were assessed for DR4/DR5 expression via flow cytometry. DOR, duration of response; MR, morphologic relapse; PD, progressive disease; RD, resistant disease.